c-Abl kinase is activated in PD substantia nigra and phosphorylates parkin at Tyr143, inhibiting its E3 ligase activity and impairing ubiquitination of α-synuclein substrates. Selective c-Abl inhibitors (K0706) block parkin inactivation, enhancing degradation of pathological substrates. Phase 2 nilotinib trial showed safety but modest efficacy, suggesting that next-generation selective inhibitors may be needed for meaningful benefit.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["c-Abl / ABL1 Kinase Activation"]
B["Mitochondrial Apoptosis"]
C["Alpha-Synuclein Phosphorylation"]
D["Parkinson Pathology"]
E["Therapeutic Inhibition"]
F["Synuclein Clearance Restoration"]
G["Neuroprotection Disease Modification"]
A --> B
A --> C
B --> D
C --> D
E --> A
E --> F
F --> G
D --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
MECH 4CLIN 1GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
c-Abl activity elevated in PD substantia nigra and…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic Hypotheses in Neurodegeneration
Hypothesis 1: TREM2 Microglial Activation as Therapeutic Target in Alzheimer's Disease
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Neurodegeneration Therapeutic Hypotheses
Hypothesis 1: TREM2 Microglial Activation
Original Confidence: 0.78 → Revised: 0.62
Weak Links
Dose-dependency assumption unexamined. TREM2 signaling has a documented biphasic character — agonistic antibodies at high concentrations can cause receptor internalization and desensitization (Painter et al., 2018). The therapeutic window for 4D9 agonism is not established in the primary literature.
Mouse model confounding. The 5xFAD/Trem2−/− cross is problematic as a therapeutic-test platform: deleting TR
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
This assessment evaluates each hypothesis across five domains:
Druggability — tractability of the target and chemical matter
Biomarkers & Model Systems — readouts and experimental platforms available
Clinical-Development Constraints — regulatory, enrollment, and endpoint considerations
Safety — on-target and off-target liabilities
Timeline & Cost Realism — phase-appropriate milestones and resource requirements
Hypothesis 1: TREM2 Microglial Activation in AD
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD", "description": "Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat expansion reduce toxic DPR proteins and RNA foci, restoring nuclear TDP-43 localization and splicing function. This is the strongest hypothesis based on genetic prevalence (~40% familial ALS, ~25% FTD), active clinical trial data (NCT04165729), and mechanistic link between repeat transcripts and downstream TDP-43 pathology. Key unresolved questions include the relative contribution of haploinsuffic
IF A53T SNCA transgenic mice (Line 61) receive chronic oral K0706 (30mg/kg/day) for 8 weeks beginning at 12 months of age, THEN markers of autophagic flux (LC3-II/LC3-I ratio, p62 degradation rate) will increase by ≥50% in substantia nigra pars compacta tissue and striatal α-synuclein aggregate burden will decrease by ≥40% compared to vehicle-treated age-matched controls.
pendingconf: 0.60
Expected outcome: ≥50% increase in LC3-II/LC3-I ratio; ≥40% reduction in α-synuclein pSer129 immunoreactive aggregates in nigrostriatal tissue
Falsified by: No increase in autophagic flux markers (LC3-II/LC3-I ratio change <20%) AND no reduction in α-synuclein aggregate load (<15% change) in K0706-treated mice compared to vehicle controls, despite adequate brain penetration (brain K0706 concentration ≥1μM)
Method: Randomized controlled study in male A53T SNCA transgenic mice (n=12/group) treated with K0706 or vehicle from 12-14 months of age, with behavioral testing (rotarod, grip strength) biweekly, followed by biochemical (Western blot for LC3, p62, parkin Tyr143 phosphorylation) and immunohistochemical (pSer129 α-synuclein) analysis of nigrostriatal tissue
IF patients with idiopathic Parkinson's disease receive orally administered selective c-Abl inhibitor (K0706 at doses achieving >80% target engagement, e.g., 300mg daily) for 6 months, THEN cerebrospinal fluid α-synuclein concentrations will decrease by ≥25% from baseline and motor disability scores (MDS-UPDRS Part III) will improve by ≥5 points compared to placebo-treated controls.
pendingconf: 0.55
Expected outcome: ≥25% reduction in CSF α-synuclein concentration; ≥5-point improvement in MDS-UPDRS Part III score
Falsified by: No statistically significant reduction in CSF α-synuclein (<10% change) AND no improvement in motor scores (≤2-point change) in the treatment arm compared to placebo, despite confirmed target engagement (≥80% ABL1 inhibition in peripheral blood mononuclear cells)
Method: Phase 2 randomized, double-blind, placebo-controlled trial (n=120) in idiopathic PD patients (Hoehn-Yahr stage 2-3) with 6-month intervention, serial CSF sampling at baseline/month 3/month 6, and MDS-UPDRS assessments at baseline/month 2/month 4/month 6
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
ABL1 — Search for structure
Click to search RCSB PDB